Effects of Cannabidiol on Marijuana-seeking in Humans

Completed

Conditions studied: Marijuana Abuse

In brief

The purpose of the proposed study is to investigate the effectiveness of cannabidiol for reducing marijuana seeking in non-treatment seeking volunteers. Cannabidiol is a cannabinoid (similar to cannabis, or marijuana) present in marijuana that alters some of the effects of marijuana. Assess the ability of acute smoked CBD pretreatment to reduce marijuana-seeking behavior and increase price-elasticity of marijuana demand.

Key facts

Study ID

NCT02777502

Run by

Wayne State University

People needed

30

Starts

2016-01-01

Expected to finish

2019-01-31

Last updated by the study team

2022-02-25

Who can join

Age: 21 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants will be males and females aged 21-45 yrs.
• Must be in generally good health.
• Volunteers may meet DSM-5 criteria for current Cannabis Use Disorder but not currently be in treatment or seeking treatment for their substance use problems.
• An observed, temperature-tested urine specimen must test positive for THC so that inclusion is not solely based on self-report.

You may not qualify if…

• Psychiatric illness other than Cannabis or Nicotine Use Disorder. Also exclusionary is a history or suspicion of psychosis or indication of behavior not conducive to compliance with the study protocol.
• Neurologic disease: structural brain abnormalities (e.g., neoplasms), cerebrovascular disease, seizures, infectious disease, history of other neurological diseases, or head trauma resulting in unconsciousness.
• Cardiovascular disease: edema, chest pain or palpitations on exertion or drug use, myocardial infarction, systolic blood pressure greater than 160 or less than 95 mmHg, or diastolic pressure greater than 95 mmHg.
• Pulmonary disease: obstructive pulmonary disease, apnea, cor pulmonale, tuberculosis, dyspnea, orthopnea, or tachypnea (> 24 breaths per minute). Current diagnosis of or treatment for asthma. History of asthma may be allowed, per the study physician's discretion.
• Systemic disease: e.g., endocrinopathies, renal or hepatic failure, active hepatitis (liver function tests > 3x normal cutoff), myxedema, hypothyroidism, adrenocortical insufficiency, Cushing syndrome, chronic GI disease, AIDS or any other autoimmune disease involving the CNS.
• Current substance use disorders other than Cannabis or Nicotine Use Disorder.
• Cognitively impairment as indicated by an estimated IQ of lower than 85. Individuals unable to give voluntary informed consent will not be enrolled. They can be neither intoxicated nor undergoing withdrawal at the time of screening and consent.
• Recent experimental participation (within past month).
• Pregnancy or lactation. Females who are heterosexually active and not using (self-report) medically approved birth control measures (e.g., sterilization, tubal ligation, birth control pills, abstinence, intrauterine device, barrier method, cervical cap combined with a spermicide) are not eligible. Women who are breastfeeding will be excluded.
• Individuals currently in, intending to seek, or court mandated for substance abuse treatment will be excluded. Finally, participants may be withdrawn from study if they do not comply with the study protocol, test positive for drugs of abuse other than marijuana on the routine urine screen or decide not to participate in the study.

Where it is running

• Tolan Park Medical Building — Detroit, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.